FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1945146502> ?p ?o ?g. }

• W1945146502 endingPage "4097" @default.
• W1945146502 startingPage "4086" @default.
• W1945146502 abstract "To evaluate the toxicity and pharmacologic behavior of the novel mushroom-derived cytotoxin irofulven administered as a 5-minute intravenous (IV) infusion daily for 5 days every 4 weeks to patients with advanced solid malignancies.In this phase I trial, 46 patients were treated with irofulven doses ranging from 1.0 to 17.69 mg/m(2) as a 5-minute IV infusion (two patients received a 1-hour infusion) daily for 5 days every 4 weeks. The modified continual reassessment method was used for dose escalation. Pharmacokinetic studies were performed on days 1 and 5 to characterize the plasma disposition of irofulven.Forty-six patients were treated with 92 courses of irofulven. The dose-limiting toxicities on this schedule were myelosuppression and renal dysfunction. At the 14.15-mg/m(2) dose level, renal dysfunction resembling renal tubular acidosis occurred in four of 10 patients and was ameliorated by prophylactic IV hydration. The 17.69-mg/m(2) dose level was not tolerated because of grade 4 neutropenia and renal toxicity, whereas the 14.15-mg/m(2) dose level was not tolerable with repetitive dosing because of persistent thrombocytopenia. Other common toxicities included mild to moderate nausea, vomiting, facial erythema, and fatigue. One partial response occurred in a patient with advanced, refractory metastatic pancreatic cancer lasting 7 months. Pharmacokinetic studies of irofulven revealed dose-proportional increases in both maximum plasma concentrations and area under the concentration-time curve, while the agent exhibited a rapid elimination half-life of 2 to 10 minutes.Given the results of this study, the recommended dose of irofulven is 10.64 mg/m(2) as a 5-minute IV infusion daily for 5 days every 4 weeks. The preliminary antitumor activity documented in a patient with advanced pancreatic cancer and the striking preclinical antitumor effects of irofulven observed on intermittent dosing schedules support further disease-directed evaluations of this agent on the schedule evaluated in this study." @default.
• W1945146502 created "2016-06-24" @default.
• W1945146502 creator A5000204204 @default.
• W1945146502 creator A5001759866 @default.
• W1945146502 creator A5002037553 @default.
• W1945146502 creator A5002106474 @default.
• W1945146502 creator A5003463083 @default.
• W1945146502 creator A5004386291 @default.
• W1945146502 creator A5011905014 @default.
• W1945146502 creator A5015548619 @default.
• W1945146502 creator A5031228775 @default.
• W1945146502 creator A5032869165 @default.
• W1945146502 creator A5052493398 @default.
• W1945146502 creator A5058053182 @default.
• W1945146502 creator A5068116160 @default.
• W1945146502 creator A5075492015 @default.
• W1945146502 creator A5077260725 @default.
• W1945146502 creator A5077682980 @default.
• W1945146502 creator A5080900202 @default.
• W1945146502 creator A5086660695 @default.
• W1945146502 date "2000-12-15" @default.
• W1945146502 modified "2023-10-18" @default.
• W1945146502 title "Phase I and Pharmacokinetic Study of Irofulven, a Novel Mushroom-Derived Cytotoxin, Administered for Five Consecutive Days Every Four Weeks in Patients With Advanced Solid Malignancies" @default.
• W1945146502 cites W1584273408 @default.
• W1945146502 cites W1892622076 @default.
• W1945146502 cites W1976274817 @default.
• W1945146502 cites W1992711716 @default.
• W1945146502 cites W2009606158 @default.
• W1945146502 cites W2017192757 @default.
• W1945146502 cites W2057388890 @default.
• W1945146502 cites W2068346906 @default.
• W1945146502 cites W2082359412 @default.
• W1945146502 cites W2084954790 @default.
• W1945146502 cites W2089361349 @default.
• W1945146502 cites W2119597015 @default.
• W1945146502 cites W2126024856 @default.
• W1945146502 cites W2158740848 @default.
• W1945146502 cites W2163509831 @default.
• W1945146502 cites W2333724269 @default.
• W1945146502 doi "https://doi.org/10.1200/jco.2000.18.24.4086" @default.
• W1945146502 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11118470" @default.
• W1945146502 hasPublicationYear "2000" @default.
• W1945146502 type Work @default.
• W1945146502 sameAs 1945146502 @default.
• W1945146502 citedByCount "50" @default.
• W1945146502 countsByYear W19451465022012 @default.
• W1945146502 countsByYear W19451465022013 @default.
• W1945146502 countsByYear W19451465022014 @default.
• W1945146502 countsByYear W19451465022015 @default.
• W1945146502 countsByYear W19451465022017 @default.
• W1945146502 countsByYear W19451465022021 @default.
• W1945146502 countsByYear W19451465022022 @default.
• W1945146502 crossrefType "journal-article" @default.
• W1945146502 hasAuthorship W1945146502A5000204204 @default.
• W1945146502 hasAuthorship W1945146502A5001759866 @default.
• W1945146502 hasAuthorship W1945146502A5002037553 @default.
• W1945146502 hasAuthorship W1945146502A5002106474 @default.
• W1945146502 hasAuthorship W1945146502A5003463083 @default.
• W1945146502 hasAuthorship W1945146502A5004386291 @default.
• W1945146502 hasAuthorship W1945146502A5011905014 @default.
• W1945146502 hasAuthorship W1945146502A5015548619 @default.
• W1945146502 hasAuthorship W1945146502A5031228775 @default.
• W1945146502 hasAuthorship W1945146502A5032869165 @default.
• W1945146502 hasAuthorship W1945146502A5052493398 @default.
• W1945146502 hasAuthorship W1945146502A5058053182 @default.
• W1945146502 hasAuthorship W1945146502A5068116160 @default.
• W1945146502 hasAuthorship W1945146502A5075492015 @default.
• W1945146502 hasAuthorship W1945146502A5077260725 @default.
• W1945146502 hasAuthorship W1945146502A5077682980 @default.
• W1945146502 hasAuthorship W1945146502A5080900202 @default.
• W1945146502 hasAuthorship W1945146502A5086660695 @default.
• W1945146502 hasConcept C112705442 @default.
• W1945146502 hasConcept C121332964 @default.
• W1945146502 hasConcept C126322002 @default.
• W1945146502 hasConcept C126894567 @default.
• W1945146502 hasConcept C142424586 @default.
• W1945146502 hasConcept C2776694085 @default.
• W1945146502 hasConcept C2777063308 @default.
• W1945146502 hasConcept C2777288759 @default.
• W1945146502 hasConcept C2778239845 @default.
• W1945146502 hasConcept C2780580376 @default.
• W1945146502 hasConcept C2780852908 @default.
• W1945146502 hasConcept C2781451048 @default.
• W1945146502 hasConcept C29730261 @default.
• W1945146502 hasConcept C71924100 @default.
• W1945146502 hasConcept C87355193 @default.
• W1945146502 hasConcept C90924648 @default.
• W1945146502 hasConcept C98274493 @default.
• W1945146502 hasConceptScore W1945146502C112705442 @default.
• W1945146502 hasConceptScore W1945146502C121332964 @default.
• W1945146502 hasConceptScore W1945146502C126322002 @default.
• W1945146502 hasConceptScore W1945146502C126894567 @default.
• W1945146502 hasConceptScore W1945146502C142424586 @default.
• W1945146502 hasConceptScore W1945146502C2776694085 @default.
• W1945146502 hasConceptScore W1945146502C2777063308 @default.
• W1945146502 hasConceptScore W1945146502C2777288759 @default.
• W1945146502 hasConceptScore W1945146502C2778239845 @default.
• W1945146502 hasConceptScore W1945146502C2780580376 @default.

• next